A Phase 2 interventional study of 18F-DCFPyL Injection in Prostate Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Active, not recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing piflufolastat in Prostatic Neoplasms — 5 open to participants now, 10 under way, none of them phase 3. piflufolastat · Prostatic Neoplasms.
Among the 24 studies testing piflufolastat in Prostatic Neoplasms, this one is the 8th largest by planned enrollment, is one of 4 that started in 2018, is one of 10 in phase 2, and was the 7th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →5 of the 24 studies testing piflufolastat in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Akiva Mintz · Sites in United States
Ages 18–120 · Healthy volunteers
OHSU Knight Cancer Institute · Sites in United States
Ages 18+ · Men only
Brigham and Women's Hospital · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18–100 · Men only
National Cancer Institute (NCI) · Sites in United States
Ages 18–120 · Men only
By country, each count listing its studies:
piflufolastat: first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 4 · Phase 4 5
First in 2014; this study’s year is marked. 4 started in 2018.
This study's planned enrollment of 150 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 55 across the 24 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 24 have an industry lead sponsor. The 10 most frequent:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is the lead sponsor of 582 studies on the registry; 71 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 68 (60%) have results posted.
78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: 12 open now, 18 under way, none of them phase 3. Of 55 finished, 35 (64%) have results posted.
Among the 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, this one is the 5th largest by planned enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2018, is one of 31 in phase 2, reaches primary completion later than 9 of the 17 other live ones, and was the 49th registered.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins’s Prostatic Neoplasms studies by the year they started, since 2002.
1 of the studies testing piflufolastat in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06099093Brigham and Women's HospitalPilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing piflufolastat in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins’s 78 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a phase II, single-center, open-label, trial to evaluate the diagnostic accuracy of PSMA-targeted 18F-DCFPyL PET/CT for detecting clinically significant prostate cancer in a screening population.
This is a phase II, single-center, open-label, trial to evaluate the diagnostic accuracy of PSMA-targeted 18F-DCFPyL PET/CT for detecting clinically significant prostate cancer in a screening population. 150 biopsy-naïve patients with an elevated PSA (2-10 ng/mL) will be enrolled in this study.
Within 28 days of informed consent, patients will undergo an 18F-DCFPyL PET/CT. All scans will be read by a single experienced radiologist who will identify regions of interest (ROI) with discrete radiotracer uptake. The maximum SUV value (SUVmax) of each ROI will be recorded. For patients without a detectable ROI, the mean SUV (SUVmean) of a 1-2 cm volume of the prostate will instead be recorded.
One to 28 days following PET/CT imaging, a systematic 12 to 14 core TRUS-guided prostate biopsy will be performed. Immediately following completion of systematic TRUS biopsies, fusion-targeted biopsies of all PET and/or MRI visible lesions will be performed, taking an additional 2 to 3 cores from each radiographic ROI. All biopsy cores will be assessed for Gleason score and percent cancer involvement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
Drug: 18F-DCFPyL Injection
A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
Also known as: PyL
Sensitivity of 18F-DCFPyL PET/CT to detect clinically significant prostate cancer on prostate biopsy relative to serum prostate specific antigen (PSA)
Measure the diagnostic accuracy of 18F-DCFPyL PET/CT and compare it with serum PSA for detecting clinically significant prostate cancer on prostate biopsy
Time frame: 4 years
Sensitivity of 18F-DCFPyL PET/CT relative to PSA
Measure the diagnostic accuracy of 18F-DCFPyL PET/CT relative to serum PSA for detecting clinically significant prostate cancer as defined by the following alternative definitions: Gleason score ≥4+3=7; Gleason score ≥3+4 or \>50% involvement of ≥1 core with Gleason score ≥3+3=6 prostate cancer; Gleason score ≥3+4 or \>70% involvement of ≥1 core with Gleason score ≥3+3=6 prostate cancer; Gleason score ≥3+4=7, or \>2 cores with Gleason score ≥3+3=6, or \>50% involvement of ≥1 core with Gleason score ≥3+3=6 prostate cancer.
Time frame: 4 years
Sensitivity of 18F-DCFPyL PET/CT for detecting clinically significant prostate cancer relative to mpMRI
Measure the diagnostic accuracy of 18F-DCFPyL PET/CT relative to mpMRI for detecting clinically significant prostate cancer by the various tested definitions
Time frame: 4 years
Sensitivity and diagnostic accuracy of 18F-DCFPyL PET/CT relative to the phi blood test for detecting clinically significant prostate cancer by the various tested definitions
Measure the diagnostic accuracy of 18F-DCFPyL PET/CT relative to the phi blood test for detecting clinically significant prostate cancer by the various tested definitions
Time frame: 4 years
Started Mar 2018 (actual). Primary completion is estimated for Mar 2028, 119 months after the start.
Of 610 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 86. This study's planned 119 months is above that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Piflufolastat
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins →